Panavance Therapeutics Inc. is a US, clinical-stage pharmaceutical company established in 2021 by the Swiss-based Avensis Pharma AG, a subsidiary of Ed. Geistlich Söhne AG für Chemische Industrie. Panavance is focused on advancing the development of GP-2250, a novel oncology therapeutic intended to improve outcomes and quality of life for patients with cancer.

With its highly capable team and strong academic and industry partnerships, Panavance is pursuing a rigorous program to bring GP-2250 to patients around the world.

Life Sciences

Pharmaceutical

Therapeutics

Panavance Therapeutics Inc.

Greg Bosch

Thomas P. Hess

Tom Hess

José Iglesias

Ben Steinmetz

Leadership Team

Scientific and Research Team

Panavance Therapeutics Inc.

Org chart

Teams

Leadership Team

Scientific and Research Team

Similar companies